Eli Lilly and Rigel Pharmaceuticals partnered in February 2021 to advance a pair of RIPK1 blockers, but the pharma in October ...

Why Wall Street loves Lilly. So what does this Wall Street analyst like about Lilly? Yesterday, Eli Lilly announced it will ...

With the recent launches of Novo Nordisk’s Wegovy pill and Eli Lilly’s Foundayo, the obesity market has started to shift ...

Eli Lilly is picking up its second in vivo CAR-T company of the year, paying $3.25 billion in upfront cash for Kelonia ...

Eli Lilly stock trades for more than $900 per share, which may appear expensive upon first glance.

Eli Lilly and Novo Nordisk are fighting to capture the weight-loss drug market. Amazon could complicate things.

A deal could be reached as soon as Monday and could include additional payments tied to Kelonia meeting certain milestones, ...

Eli Lilly’s deal for Kelonia, which develops blood cancer therapies, could come as early as Monday.

After entering the CAR T space in February, Eli Lilly is “jumping into in vivo CAR-T with both feet” with the acquisition of ...

Foundayo was approved in the U.S. on April 1, with prescriptions accepted immediately on LillyDirect, while shipping started ...

Just a few months after ripping up the central nervous system-focused portion of its RIPK1 deal with Rigel Pharmaceuticals, ...

Eli Lilly is in advanced talks to acquire biotech firm Kelonia ‌Therapeutics for more than $2 billion, the Wall ‌Street ...